Biopolym. Cell. 2024; 40(4):298-304.
http://dx.doi.org/10.7124/bc.000B05
Molecular Biomedicine
ZFP36 expression profiles in breast tumors of different stages and hormonal receptor status
1Hubiernatorova A. O., 2Syvak L. A., 3Verovkina N. O., 1Kropyvko S. V.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143
  2. National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine
    53, Yuriia Illienka St., Kyiv, 04050, Ukraine
  3. Brown University. Department of Pathology and Laboratory Medicine
    02906, Providence RI, USA

Abstract

Aim. in current study we investigated how ZFP36 expression varies in breast cancer tumors of different histological types, grades, metastatic status, as well as in tumors with different progesterone and human EGFR receptor 2 (HER2) status to assess its use as a potential breast cancer biomarker. Methods. RT-qPCR. Results. we show that ZFP36 expression is elevated in T1-2 and N0-N1 tumors compared to adjacent tissues and T3-4 and N2 tumors, respectively. We also show that ZFP36 expression does not vary in samples with different PR status, but significantly increases with HER2 amplification. Conclusions. ZFP36 is a promising candidate to the HER2-enriched breast cancer biomarker, although further studies are necessary for verification.
Keywords: gene expression, carcinogenesis, breast cancer, ZFP36, TTP
Full text: (PDF, in English)

References

[1] Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pagès G. Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Mol Biol Cell. 2007; 18(11):4648-58.
[2] Brooks SA, Blackshear PJ. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim Biophys Acta. 2013; 1829(6-7):666-79.
[3] Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018; 27(11):1376-83.
[4] Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res. 2009; 69(12):5168-76.
[5] Griseri P, Bourcier C, Hieblot C, Essafi-Benkhadir K, Chamorey E, Touriol C, Pagès G. A synonymous polymorphism of the Tristetraprolin (TTP) gene, an AU-rich mRNA-binding protein, affects translation efficiency and response to Herceptin treatment in breast cancer patients. Hum Mol Genet. 2011; 20(23):4556-68.
[6] Fallahi M, Amelio AL, Cleveland JL, Rounbehler RJ. CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin. PLoS One. 2014; 9(12):e115517.
[7] Kropyvko S, Hubiernatorova A, Mankovska O, Lavrynenko K, Syvak L, Verovkina N, Lyalkin S, Ivasechko I, Stoika R, Rynditch A. Tristetraprolin expression levels and methylation status in breast cancer. Gene Reports. 2023; 30(1):101718.
[8] Hubiernatorova AO, Kropyvko S V. Doxorubicin affects expression of the ZFP36 and CTTN genes in MCF7 cell line. Biopolym Cell. 2024; 40(2):127-35.
[9] Hortobagyi GN, Edge SB, Giuliano A. New and Important Changes in the TNM Staging System for Breast Cancer. Am Soc Clin Oncol Educ Book. 2018; 38:457-67.
[10] Drury S, Anderson H, Dowsett M. Selection of REFERENCE genes for normalization of qRT-PCR data derived from FFPE breast tumors. Diagn Mol Pathol. 2009; 18(2):103-7.
[11] Lyng MB, Laenkholm AV, Pallisgaard N, Ditzel HJ. Identification of genes for normalization of real-time RT-PCR data in breast carcinomas. BMC Cancer. 2008; 8:20.
[12] Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004; 313(4):856-62.
[13] Oh E, Lee H. Transcriptomic data in tumor-adjacent normal tissues harbor prognostic information on multiple cancer types. Cancer Med. 2023; 12(10):11960-70.
[14] Aran D, Camarda R, Odegaard J, Paik H, Oskotsky B, Krings G, Goga A, Sirota M, Butte AJ. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat Commun. 2017; 8(1):1077.
[15] Telloni SM. Tumor Staging and Grading: A Primer. Methods Mol Biol. 2017; 1606:1-17.
[16] Tomaskovic-Crook E, Thompson EW, Thiery JP. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 2009; 11(6):213.
[17] Takaku M, Grimm SA, Wade PA. GATA3 in Breast Cancer: Tumor Suppressor or Oncogene? Gene Expr. 2015; 16(4):163-8.
[18] Creighton CJ. The molecular profile of luminal B breast cancer. Biologics. 2012; 6:289-97.
[19] Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A. 2004; 101(27):10137-42.
[20] Chen YL, Jiang YW, Su YL, Lee SC, Chang MS, Chang CJ. Transcriptional regulation of tristetraprolin by NF-κB signaling in LPS-stimulated macrophages. Mol Biol Rep. 2013; 40(4):2867-77.